Opening book details…
Can I read High-dose Intensity-modulated Radiotherapy for Prostate Cancer Using Daily Fiducial Marker-based Position Verification: Acute and Late Toxicity in 331 Patients on EtoBox?
High-dose Intensity-modulated Radiotherapy for Prostate Cancer Using Daily Fiducial Marker-based Position Verification: Acute and Late Toxicity in 331 Patients by Irene M Lips; Homan Dehnad; Carla H van Gils; Arto E Boeken Kruger; Uulke A van der Heide; Marco van Vulpen is a Medicine article available to read on EtoBox.
What is High-dose Intensity-modulated Radiotherapy for Prostate Cancer Using Daily Fiducial Marker-based Position Verification: Acute and Late Toxicity in 331 Patients about?
We evaluated the acute and late toxicity after high-dose intensity-modulated radiotherapy (IMRT) with fiducial marker-based position verification for prostate cancer. Between 2001 and 2004, 331 patients with prostate cancer received 76 Gy in 35 fractions using IMRT combined with fiducial marker-based position verification. The symptoms before treatment (pre-treatment) and weekly during treatment (acute toxicity) were scored using the Common Toxicity Criteria (CTC). The goal was to score late toxicity according to the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) scale with a follow-up time of at least three years. Twenty-two percent of the patients experienced pre-treatment grade ≥ 2 genitourinary (GU) complaints and 2% experienced grade 2 gastrointestinal (GI) complaints. Acute grade 2 GU and GI toxicity occurred in 47% and 30%, respectively. Only 3% of the patients developed acute grade 3 GU and no grade ≥ 3 GI toxicity occurred. After a mean follow-up time of 47 months with a minimum of 31 months for all patients, the incidence of late grade 2 GU and GI toxicity was 21% and 9%, respectively. Grade ≥ 3 GU and GI toxicity
Who reads High-dose Intensity-modulated Radiotherapy for Prostate Cancer Using Daily Fiducial Marker-based Position Verification: Acute and Late Toxicity in 331 Patients?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Irene M Lips; Homan Dehnad; Carla H van Gils; Arto E Boeken Kruger; Uulke A van der Heide; Marco van Vulpen
- Publisher
- BioMed Central; Springer (Biomed Central Ltd.); [London]: BioMed Central, 2006-; Springer Science and Business Media LLC; Society for Mining, Metallurgy and Exploration Inc. (ISSN 1748-717X)
- Published
- 2008
- Language
- EN
- Field
- Medicine (Health Sciences)